Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

Y
Yamamoto, Mihoko

Division of Hematology, UNIFESP
1227 - Concomitant use of venetoclax 100 mg and ketoconazole to treat CLL in a public center in Brazil
Mihoko Yamamoto
Favorite
Yáñez, Lucrecia

Servcio Cántabro de Salud
1043 - Regulation of the NF-kB pathway by NEDDylation in chronic lymphocytic leukemia: Beyond IkB
Lucrecia Yáñez
Favorite
Yang, Chao-Yie

Department of Internal Medicine, Pharmacology and Medicinal Chemistry, Rogel Cancer Center, University of Michigan
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Chao-Yie Yang
Favorite
Yang, Dajun

Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Inc., and State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Dajun Yang
Favorite
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Dajun Yang
Favorite
Yang, Keri

BeiGene USA, Inc.
2013 - Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Keri Yang
Favorite
Yang, Shenmiao

Peking University Institute of Hematology, Peking University People’s Hospital
1151 - The Impact of BTK Inhibitors on COVID-19 Outcomes in Patients with Chronic Lymphocytic Leukemia: A real-world study in the Omicron wave
Shenmiao Yang
Favorite
Yannakou, Costas

Epworth Healthcare, Freemasons Hospital and University of Melbourne
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Costas Yannakou
Favorite
Yan, Xiao Jie

The Feinstein Institute for Medical Research
1049 - Impact of T-cell co-stimulatory molecule CLECL1 expressing CLL cells on CLL disease progression and transformation to Richter's syndrome
Xiao Jie Yan
Favorite
Yan, Yuting

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College
1127 - Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
Yuting Yan
Favorite
1214 - An Investigation into the Differences between Western and Chinese population with Chronic Lymphocytic Leukemia
Yuting Yan
Favorite
Yates, Francesca

Cancer Research UK Clinical Trials Unit, University of Birmingham
3001 - Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Francesca Yates
Favorite
Yavuz, Boran

Dokuz Eylul University, Division of Hematology
4003 - VENETOCLAX TREATMENT OF REFRACTORY ITP IN CLL
Boran Yavuz
Favorite
Yazji, Salim

Oncternal Therapeutics
2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.
Salim Yazji
Favorite
Ye, Jordan
2020 - NX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders
Jordan Ye
Favorite
Ye, Xiaomei

Evidera PPD
2021 - Health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso-cel in TRANSCEND CLL 004
Xiaomei Ye
Favorite
Yin, Yan

Ascentage Pharma (Suzhou) Co., Ltd.
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Yan Yin
Favorite
Yin, Yanping

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital
1052 - PI3K inhibitor-resistant B-cell lymphomas show distinct functional phenotypes characterized by sensitivity to Bcl-2- or proteasome-inhibition
Yanping Yin
Favorite
1135 - Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline
Yanping Yin
Favorite
Yi, Shuhua

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College
1127 - Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
Shuhua Yi
Favorite
1214 - An Investigation into the Differences between Western and Chinese population with Chronic Lymphocytic Leukemia
Shuhua Yi
Favorite
Yong, Alan

AstraZeneca
1207 - A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naïve chronic lymphocytic leukemia
Alan Yong
Favorite
York, Nick

CLL Advocates Network
1108 - Uncovering the immune-related challenges facing people with chronic lymphocytic leukaemia
Nick York
Favorite
1147 - Global Perspectives through multi stakeholder mapping of lived experience with CLL – insights to improve equity, services, and unmet need
Nick York
Favorite
Young Lee, Che

The University of Texas MD Anderson Cancer Center
1208 - The HEALTH4CLL study: optimization of behavioral interventions for patients with chronic lymphocytic leukemia
Che Young Lee
Favorite
Ysebaert, Loic

IUCT Oncopole
1114 - Pharmacokinetics of idelalisib and outcomes
Loic Ysebaert
Favorite
1216 - Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 Rearrangement, an update from the FILO group
Loic Ysebaert
Favorite
1221 - Occurrence and Evolution of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia Patients treated with Venetoclax: a study of the French Innovative Leukemia Organization (FILO).
Loic Ysebaert
Favorite
4002 - Longitudinal CITE-Seq analyses of the peripheral blood identify transcriptomic signatures associated with progression and transformation under targeted therapy
Loic Ysebaert
Favorite
4005 - STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR): a randomized phase 2 study from the FILO-CLL group
Loic Ysebaert
Favorite
Yuan, Lingli

Department of Hematology, The Second Xiangya Hospital, Central South University
1014 - Clonal architecture and single-cell transcriptome landscape in Richter’s syndrome
Lingli Yuan
Favorite
Yu, Ji
1048 - SH2-Flow: A Multiplex Single Cell Phosphotyrosine Profiling Tool for B-cell Malignancies
Ji Yu
Favorite
Yu, Joseph

Department of Medical Oncology, Dana-Farber Cancer Institute
1040 - Exploring the impact of germline ATM mutations in cancer susceptibility and inheritance in chronic lymphocytic leukemia
Joseph Yu
Favorite
Yung, Stephanie
2020 - NX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders
Stephanie Yung
Favorite
Yuste, Maria

Quirónsalud
1116 - SAFETY PROFILE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA UNDERGOING TREATMENT WITH 1ST AND 2ND GENERATION BRUTON TYROSINE KINASE INHIBITORS: MULTICENTRIC REAL-WORLD EXPERIENCE
Maria Yuste
Favorite
Yu, Ying

State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College
1127 - Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
Ying Yu
Favorite
Yu, Zhen

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
1214 - An Investigation into the Differences between Western and Chinese population with Chronic Lymphocytic Leukemia
Zhen Yu
Favorite